Fiera Capital Corp Boosts Position in Cencora, Inc. (NYSE:COR)

Fiera Capital Corp raised its stake in Cencora, Inc. (NYSE:COR - Free Report) by 20.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,921 shares of the company's stock after purchasing an additional 5,171 shares during the quarter. Fiera Capital Corp's holdings in Cencora were worth $8,321,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of COR. Net Worth Advisory Group increased its position in shares of Cencora by 1.4% during the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock valued at $736,000 after acquiring an additional 36 shares during the last quarter. Obermeyer Wealth Partners increased its position in shares of Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock valued at $758,000 after acquiring an additional 36 shares during the last quarter. Cromwell Holdings LLC increased its position in shares of Cencora by 9.5% during the first quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock valued at $125,000 after acquiring an additional 39 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC increased its position in shares of Cencora by 2.7% during the first quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,565 shares of the company's stock valued at $435,000 after acquiring an additional 41 shares during the last quarter. Finally, Private Trust Co. NA increased its position in shares of Cencora by 2.5% during the first quarter. Private Trust Co. NA now owns 1,933 shares of the company's stock valued at $538,000 after acquiring an additional 47 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

COR has been the subject of a number of research analyst reports. Bank of America increased their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Morgan Stanley set a $330.00 price objective on Cencora and gave the company an "equal weight" rating in a report on Wednesday, July 16th. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $274.00 to $337.00 in a report on Tuesday, June 3rd. Citigroup increased their price objective on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, Robert W. Baird increased their price objective on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $309.83.

Cencora Price Performance

NYSE:COR traded up $2.23 during trading hours on Friday, hitting $288.31. 1,140,211 shares of the company's stock traded hands, compared to its average volume of 941,703. The firm has a market cap of $55.88 billion, a P/E ratio of 33.45, a P/E/G ratio of 1.42 and a beta of 0.57. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35. The business's fifty day simple moving average is $292.97 and its two-hundred day simple moving average is $276.02. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $3.80 earnings per share. On average, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were given a dividend of $0.55 per share. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.8%. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction dated Tuesday, July 22nd. The stock was sold at an average price of $292.67, for a total transaction of $4,266,543.26. Following the sale, the chairman owned 309,913 shares in the company, valued at $90,702,237.71. This trade represents a 4.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 4,968 shares of Cencora stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the completion of the transaction, the chief executive officer owned 42,351 shares in the company, valued at approximately $12,455,852.61. This represents a 10.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,125 shares of company stock worth $9,993,789 in the last 90 days. Company insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.